PT Lippo Karawaci Tbk · IDX:LPKR
PT Lippo Karawaci Tbk — Q1 2022 Earnings Presentation
36 slides from PT Lippo Karawaci Tbk's earnings presentation, Apr 28, 2022
Slide 1: PT Lippo Karawaci Tbk 1Q22 Results Presentation
PT Lippo Karawaci Tbk 1Q22 Results Presentation April 28, 2022
Slide 2: Forward looking statements
Forward looking statements Certain statements in this release are or may be forward- looking statements. These statements typically contain words such as "will", "expects" and "anticipates" and words of similar import. By their nature, forward looking statements involve a number of risks and uncerta
Slide 3: Introduction and Background
INTRODUCTION AND BACKGROUND 3
Slide 4: Brief introduction to Lippo Karawaci
Brief introduction to Lippo Karawaci To be a leading real estate ▪ To win the hearts and minds of and healthcare company our customers through quality in Asia, committed to homes, healthcare and lifestyle advancing the well-being offerings, as well as people- of those we serve. VISION centric servic
Slide 5: Key Investment Highlights
Key Investment Highlights 1 Large landbank and strong growth in marketing sales that is expected to remain elevated in coming years, generating positive 2 cashflow Real estate 26% Controlling stake in the largest Strong management hospital operator in Indonesia with team with focus on over 41 hospit
Slide 6: 1Q22 Business Highlights
LIPPO 1Q22 BUSINESS HIGHLIGHTS
Slide 7: Business Highlights
Business Highlights Stable 1Q22 LPKR revenue posted at Rp 3.34tn. Demand for landed residential products remained to be strong. PILLAR 1: REAL ESTATE 1Q22 marketing sales of Rp 1.21tn Successfully launched Cendana 100% hand-over of Cendana Homes with total 1,635 unit sold, making up Cove Verdant (so
Slide 8: Financial Update
LIPPO FINANCIAL UPDATE
Slide 9: 1Q22 performance reduced as Healthcare performance normalised from Covid gain in 1Q21
1Q22 performance reduced as Healthcare performance normalised from the significant Covid gain in 1Q21* Revenue Gross Profit 1,587 3,550 CAGR +3.8% 1,433 3,336 CAGR +3.7% 3,101 1,329 1Q20 1Q21 1Q22 NPAT 1Q20 1Q21 1Q22 (449) (567) CAGR +48.2 1Q20 1Q21 1Q22 (2,116) 9 *1Q21 normalized to exclude LMIRT c
Slide 10: Financial Results
Financial Results 1Q22 1Q21* Real Estate Healthcare Lifestyle Total Particulars Real Estate Healthcare Lifestyle Total Real Estate Healthcare Lifestyle Total Rp % Rp % Rp % Rp % Revenue 865 2222 249 3336 1005 2299 246 3550 -140 -13.9% -77 -3.3% 3 1.22% -214 -6.03% Gross Profit 415 842 176 1433 420 9
Slide 11: Financial Results
Financial Results Revenue EBITDA (RpBn) (RpBn) 21 Real Estate - 226 3 Dev. - 140 - 77 -- Real Life Healthcare Life Healthcare Estate style style Dev. 813 3,550 3336 608 1Q21 1Q22 1Q21 1Q22 - 1Q22 saw consolidated revenues down by 6% YoY as a - EBITDA in 1Q22 was down by 25% YoY to Rp608bn from resul
Slide 12: Operating Cash Flow Continues to Improve from Marketing Sales & Recurring Revenue
Operating Cash Flow Continues to Improve from Marketing Sales & Recurring Revenue Historical Operating Cashflow Cash Breakdown (Mar 2022) (RpBn) (RpBn) 2,000 1,628 1,000 106 SILO - 1,716 LPCK (1,000) GMTD (2,000) 2,328 Holdco cash (3,000) -2,373 (4,000) -3,409 374 (5,000) -4,539 16 2018 2019 2020 20
Slide 13: Liquidity Continues to Stabilise from Increase in Marketing Sales and Improved Business Performance
Liquidity Continues to Stabilise from Increase in Marketing Sales and Improved Business Performance Historical Net Debt(1) Historical Holdco Cash Rp bn 000 0.60 2,567 2,418 000 0.52 0.50 2,328 000 0.38 0.40 2,182 0.40 2,096 000 0.30 000 12,803 0.22 10,732 8,880 0.20 000 8,586 7,395 000 0.10 - - 2018
Slide 14: Pillar 1: Real Estate Overview
PILLAR 1: REAL ESTATE OVERVIEW 14
Slide 15: Real Estate Business Key Metrics
Real Estate Business Key Metrics Marketing sales achieved Revenue decreased 100% handover status of Rp1.21tn (23% of 2022 13.9% Cendana Homes launched target). Strong sales led To in 2020. Two other landed by launches of several residential clusters ready residential for first-home Rp865bn for hando
Slide 16: 1Q22 is Continuing Sales Growth from 2021 with Innovation in Products Offering
1Q22 is Continuing Sales Growth from 2021 with Innovation in Products Offering 2022 Marketing Sales Is to Continue Growth in 2022 Greater Jakarta is the main contributor to sales in Q1 6,000 5,200 2.2% 4,964 5,000 0.0% 4,000 6.7% Lippo Village 2,670 8.6% Cikarang 3,000 1,846 5.2% Jakarta 2,000 1,598
Slide 17: Business Highlights (cont'd)
Business Highlights (cont’d) Successful launched of several clusters, showing strong demand in residentials Q1 2022 Milestone January 2022 February 2022 March 2022 • Launching Uptown @ • Launching Cendana • Launching Brava @ Himalaya with Lippo Cikarang Cove Verdant (252 higher ASP Rp 4.1bn units so
Slide 18: Pillar 2: Healthcare Overview
PILLAR 2: HEALTHCARE OVERVIEW 18
Slide 19: 1Q22 Financial Result Summary
1Q22 Financial Result Summary Revenue decreased EBITDA was lower by Net Profit decreased 3.3% 37% 51% Siloam faced a situation to and booked at to where COVID admittances were very low and the IDR 2.22tn IDR392bn IDR130bn spike in COVID cases also in 1Q22 vs 1Q21 in 1Q22 vs 1Q21 in 1Q22 vs 1Q21 caus
Slide 20: 1Q22 vs 4Q21 and 1Q22 vs 1Q20 Financial Results
1Q22 vs 4Q21 and 1Q22 vs 1Q20 Financial Results Revenue lower by EBITDA lower by Revenue increased EBITDA was higher by by 0.7% 6% in 1Q22 in 1Q22 18.4% 23.7% vs 4Q21 compared to 4Q21 in 1Q22 vs 1Q20 in 1Q22 compared to 1Q20 To put Siloam’s results in context, it is important to review them with lik
Slide 21: Highest Inpatient Admissions and Outpatient Visits in 1Q22
Highest Inpatient Admissions and Outpatient Visits in 1Q22 Inpatient admissions and outpatient visits were higher in the first quarter of 2022 than in any quarter over the previous 7 quarters. Inpatient Admissions 60,000 51,235 40,000 20,000 0 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 Inpatient Days (
Slide 22: Revenue Growth by Payer Group (Rp bn)
Revenue Growth by Payer Group (Rp bn) 22
Slide 23: Manage Service Model
Manage Service Model Siloam opened its first hospital under its new managed service business line. Via this business line an external investor uses their own capital to build and fit out the hospital and once built, Siloam manages the hospital. We then leverage our brand and integrate our billing sy
Slide 24: Recovery of Tourism – Siloam Bali Hospitals
Recovery of Tourism – Siloam Bali Hospitals EBITDA Contribution (IDR bn) SHDP, BIMC Kuta, BIMC Nusa Dua 54 32 19 22 23 17 14 14 5 1Q20 2Q20 3Q20 4Q20 1Q21 2Q21 3Q21 4Q21 1Q22 Siloam’s Kuta and Nusa Dua hospital in Bali have always catered for the tourism market. Throughout COVID their revenue and pa
Slide 25: Strengthening Digital Channels Capabilities
Strengthening Digital Channels Capabilities Siloam has continued to strengthen its digital capabilities and integrate them further into our operating model. We’ve revamped our website to make it more user friendly, informative and importantly easier for patients to make bookings online. We’ve contin
Slide 26: Pillar 3: Lifestyle Overview
PILLAR 3: LIFESTYLE OVERVIEW 26
Slide 27: Malls and Hotels see Recovery Post Covid Lockdowns
Malls and Hotels see Recovery Post Covid Lockdowns Malls Hospitality – Aryaduta Hotels • 1Q22 revenue of Rp80bn and EBITDA of • 1Q22 revenue of Rp57bn grew by 30% YoY as Rp23bn was impacted by the Omicron wave. occupancy continues to be improve with looser travel restrictions. • Footfall traffic slo
Slide 28: Looking Ahead
LIPPO LOOKING AHEAD
Slide 29: LPKR is on a Positive Growth Trajectory, Supported by Successful Corporate Transformation
LPKR is on a Positive Growth Trajectory, Supported by Successful Corporate Transformation Lippo Karawaci’s strategic transformation over the past 3 years has positioned us well for a positive growth trajectory. Based on our strong 2021 performance, we have greater conviction in our long–term strateg
Slide 30: LPKR is on a Positive Growth Trajectory (Healthcare)
LPKR is on a Positive Growth Trajectory, Supported by Successful Corporate Transformation 2. Healthcare: Strong Fundamentals with Sustained Demand for Quality Healthcare Post-Pandemic The growth of Siloam’s non-COVID business was sustained through 1Q2022 despite the Omicron impact, reflecting contin
Slide 31: LPKR is on a Positive Growth Trajectory (Lifestyle)
LPKR is on a Positive Growth Trajectory, Supported by Successful Corporate Transformation 3. Lifestyle: Turnaround in Visitor Footfall and Occupancy Post-Pandemic Our Lifestyle businesses are on the path to recovery to pre-COVID levels. We have seen higher mall visitor footfall and hotel occupancy a
Slide 32: Appendices
LIPPO APPENDICES
Slide 33: Consolidated Statement of Profit and Loss
Consolidated Statement of Profit and Loss Note: Above reported metrics for 1Q21 are consolidated for LMIRT. 33
Slide 34: Consolidated Statement of Financial Position
Consolidated Statement of Financial Position (Rp Billion Consolidated) ASSETS 1Q22 FY21 LIABILITIES & STOCKHOLDERS' EQUITY 1Q22 FY21 CURRENT ASSETS CURRENT LIABILITIES Cash & Cash Equivalent 4,434 4,888 Bank Loans 1,059 1,352 Trade Accounts Receivable 1,825 1,633 Lease Liabilities 867 623 Inventorie
Slide 35: Thank You
LIPPO THANK YOU
Slide 36: Investor Relations
INVESTOR RELATIONS PT LIPPO KARAWACI TBK Head of Investor Relations Dr. Randi Bayu Prathama Email: [email protected] Mobile: +62811225873 Deputy Head of Investor Relations Indra Agina Sinuraya Email: [email protected] Mobile: +6281310008957 36